Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 21, Issue 1, 2016, Pages 127-137

  Watson, Chris J ^a,b   Horgan, Stephen ^a   Neary, Roisin ^a   Glezeva, Nadezhda ^a   Tea, Isaac ^a   Corrigan, Niamh ^a   McDonald, Ken ^b   Ledwidge, Mark ^b   Baugh, John ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST MICHAEL'S HOSPITAL   (Ireland)

Author keywords

5 azacytidine; cardiac fibrosis; DNA methylation; epigenetics; hypertension; hypertrophy

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AZACITIDINE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; ACTA2 PROTEIN, HUMAN; ACTIN; CARRIER PROTEIN; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; MYOSIN-BINDING PROTEIN C; TGFB1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL SIZE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DNA METHYLATION; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; EPIGENETICS; FIBROBLAST CULTURE; GENE EXPRESSION REGULATION; HEART FIBROBLAST; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MUSCLE CELL; MYBP C3 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FIBROBLAST; FIBROSIS; GENETIC EPIGENESIS; GENETICS; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ACTINS; ANIMALS; AZACITIDINE; CARDIOMEGALY; CARRIER PROTEINS; CELLS, CULTURED; COLLAGEN TYPE I; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; MALE; MYOCYTES, CARDIAC; RATS, INBRED SHR; RATS, INBRED WKY; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR REMODELING;

EID: 84951335544     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248415591698     Document Type: Article

References (44)

1. Frey N, Katus HA, Olson EN, Hill JA,. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004; 109 (13): 1580-1589.
2. Levy D, Murabito JM, Anderson KM, Christiansen JC, Castelli WP,. Echocardiographic left ventricular hypertrophy: clinical characteristics. The Framingham Heart Study. Clin Exp Hypertens A. 1992; 14 (1-2): 85-97.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP,. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322 (22): 1561-1566.
4. Prugger C, Keil U, Wellmann J, et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens. 2011; 29 (8): 1641-1648.
5. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002; 347 (5): 305-313.
6. Dhingra R, Vasan RS,. Diabetes and the risk of heart failure. Heart Fail Clin. 2012; 8 (1): 125-133.
7. Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP,. Patterns of myocardial fibrosis. J Mol Cell Cardiol. 1989; 21 (suppl 5): 121-131.
8. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT,. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res. 1989; 64 (6): 1041-1050.
9. Wynn TA,. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214 (2): 199-210.
10. Huang SK, Fisher AS, Scruggs AM, et al. Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol. 2010; 177 (5): 2245-2255.
11. Sanders YY, Pardo A, Selman M, et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008; 39 (5): 610-618.
12. Robinson CM, Neary R, Levendale A, Watson CJ, Baugh JA,. Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with Thy-1 promoter methylation and the development of a pro-fibrotic Phenotype. Respir Res. 2012; 13: 74.
13. Sanders YY, Ambalavanan N, Halloran B, et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Resp Crit Care. 2012; 186 (6): 525-535.
14. Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 2010; 16 (5): 544-550.
15. Yang JJ, Tao H, Huang C, et al. DNA methylation and MeCP2 regulation of PTCH1 expression during rats hepatic fibrosis. Cell Signal. 2013; 25 (5): 1202-1211.
16. Gao S, Long CL, Wang RH, Wang H,. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res. 2009; 83 (3): 444-456.
17. Peng H, Carretero OA, Vuljaj N, et al. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation. 2005; 112 (16): 2436-2445.
18. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J,. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol. 2006; 48 (1): 89-96.
19. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005; 288 (1): E125-E132.
20. He HB, Yang XZ, Shi MQ, Zeng XW, Wu LM, Li LD,. Comparison of cardioprotective effects of salvianolic acid B and benazepril on large myocardial infarction in rats. Pharmacol Rep. 2008; 60 (3): 369-381.
21. Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015; 36 (18): 1123-1135.
22. Merkulov S, Chen X, Chandler MP, Stelzer JE,. In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfunction in cardiac myosin binding protein C null mice. Cir Heart Fail. 2012; 5 (5): 635-644.
23. Lee TM, Lin MS, Chang NC,. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am J Physiol Heart Circ Physiol. 2007; 293 (2): H968-H977.
24. Iyer A, Fenning A, Lim J, et al. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol. 2010; 159 (7): 1408-1417.
25. Kao YH, Liou JP, Chung CC, et al. Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int J Cardiol. 2013; 168 (4): 4178-4183.
26. Roncarati R, Anselmi CV, Losi MA, et al. Circulating miR-29a, among other upregulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013; 63 (9): 920-927.
27. Dai Y, Khaidakov M, Wang X, et al. MicroRNAs involved in the regulation of postischemic cardiac fibrosis. Hypertension. 2013; 61 (4): 751-756.
28. Thum T, Lorenzen JM,. Cardiac fibrosis revisited by microRNA therapeutics. Circulation. 2012; 126 (7): 800-802.
29. Doggrell SA, Brown L,. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res. 1998; 39 (1): 89-105.
30. Palmieri V, Dahlof B, DeQuattro V, et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol. 1999; 34 (5): 1625-1632.
31. Fan D, Takawale A, Basu R, et al. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovasc Res. 2014; 103 (2): 268-280.
32. Brilla CG, Funck RC, Rupp H,. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000; 102 (12): 1388-1393.
33. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL,. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002; 105 (21): 2512-2517.
34. Kuwahara F, Kai H, Tokuda K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004; 43 (4): 739-745.
35. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL,. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010; 56 (2): 225-231.
36. Watson CJ, Collier P, Tea I, et al. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. Hum Mol Genet. 2014; 23 (8): 2176-2188.
37. Tao H, Yang JJ, Chen ZW, et al. DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2. Toxicology. 2014; 323C: 42-50.
38. Xiao D, Dasgupta C, Chen M, et al. Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats. Cardiovasc Res. 2014; 101 (3): 373-382.
39. Kim YS, Kang WS, Kwon JS, et al. Protective role of 5-azacytidine on myocardial infarction is associated with modulation of macrophage phenotype and inhibition of fibrosis. J Cell Mol Med. 2014; 18 (6): 1018-1027.
40. Movassagh M, Choy MK, Goddard M, Bennett MR, Down TA, Foo RS,. Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PloS One. 2010; 5 (1): e8564.
41. Meurs KM, Kuan M,. Differential methylation of CpG sites in two isoforms of myosin binding protein C, an important hypertrophic cardiomyopathy gene. Environ Mol Mutagen. 2011; 52 (2): 161-164.
42. Movassagh M, Choy MK, Knowles DA, et al. Distinct epigenomic features in end-stage failing human hearts. Circulation. 2011; 124 (22): 2411-2422.
43. Esteller M,. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007; 16 (spec no. 1): R50-R59.
44. Esteller M,. Epigenetics in cancer. N Engl J Med. 2008; 358 (11): 1148-1159.